0 -0.000232783053393597 -0.000232783053393597 0.00312697235641258 0.00168707718078131 0.0012071121222375 0.00108712085760168 0.00900654432357331
Sign Up Today X
Thanks for submitting the form.
Stockreport

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock (MIRM)  More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) worldwide. Sales of Livmarli have been rising steadily since its approval and launch in 2021. The FDA approved a label expansion for Livmarli oral solution to include the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (“PFIC”) in March. Also, during the second quarter of 2024, Livmarli was approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States. The European Commission approved Livmarli for the treatment of PFIC in patients aged three months and older in July. In the first half of 2024, Livmarli generated sales worth $90.1 million, up 46.3% on a year-over-year basis. The label expansion and the continuous demand for the drug should drive sales further in the days ahead. Shares of Mirum have rallied 37.8% year to date against the industry's decrease of 1.7%. [Read more]
IMPACT SNAPSHOT EVENT TIME: MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MIRM alerts
from News Quantified
MIRM
NEWS
MIRM
Earnings
MIRM
Analyst Actions
MIRM
SEC Filings
Stockreport

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) worldwide. Sales of Livmarli have been rising steadily since its approval and launch in 2021. The FDA approved a label expansion for Livmarli oral solution to include the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (“PFIC”) in March. Also, during the second quarter of 2024, Livmarli was approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States. The European Commission approved Livmarli for the treatment of PFIC in patients aged three months and older in July. In the first half of 2024, Livmarli generated sales worth $90.1 million, up 46.3% on a year-over-year basis. The label expansion and the continuous demand for the drug should drive sales further in the days ahead. Shares of Mirum have rallied 37.8% year to date against the industry's decrease of 1.7%. [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS